Zenbexus Phase 3 Success: Positive Pipeline Signal but Near-Term Risks Unchanged

What happened

Bristol Myers Squibb announced topline results from the Phase 3 EXCALIBER-RRMM study showing Zenbexus reduced the risk of disease progression or death by 51% in relapsed/refractory multiple myeloma. This is a promising late-stage oncology data point that could strengthen BMY's growth portfolio, which grew 17% to $26.4 billion in FY2025 and is the strategic counterweight to legacy erosion. The result is particularly important because BMY's legacy portfolio (Revlimid, Eliquis) faces known step-downs in 2026, including IRA price resets and Revlimid generic volume-cap removal. However, the announcement lacks details on the comparator arm, safety profile, and commercialization timeline, and Zenbexus is not yet a revenue contributor; near-term financials still hinge on Eliquis volume and gross margin stability. Therefore, while the data is a positive pipeline signal, it does not resolve the central 2026 bridge-year question of whether BMY can sustain margins amid policy-driven price pressures.

Implication

The Zenbexus result could, over time, reinforce BMY's oncology growth narrative and reduce the risk that the growth portfolio fails to offset legacy declines. However, the immediate investment case still depends on Eliquis volume and gross margin defense in 2026, as outlined in the master report. The stock's reaction may be muted because the trial details are limited and Zenbexus is not yet commercial. Investors should monitor upcoming data disclosures and management commentary on how Zenbexus fits into the growth portfolio's trajectory. If the data holds up and BMY's 2026 operational metrics stay within guidance, the bull case strengthens; otherwise, the WAIT rating remains appropriate.

Thesis delta

The Zenbexus data adds an incremental positive to BMY's pipeline thesis, potentially improving the odds that the growth portfolio can eventually replace legacy revenue. However, it does not address the near-term bridge-year risks around Eliquis pricing and gross margin. The overall rating remains WAIT, with the same key checkpoints: Eliquis growth and margin stability over the next two quarters.